Lung cancer can spread to other parts of the body through the bloodstream or the lymphatic system, a biological process known as metastasis. When cancer cells break away from the primary tumour in the lung, they can travel to distant organs and begin to grow as secondary tumours. Understanding how and where lung cancer spreads is a vital part of the diagnostic and staging process in the UK, as it determines which treatment pathways are most appropriate for the patient.
What We’ll Discuss in This Article
- The biological mechanisms of cancer cell migration through the body.
- Common sites where lung cancer typically spreads or metastasises.
- The difference between primary lung cancer and secondary tumours.
- How the lymphatic system acts as a pathway for cancer cells.
- The role of advanced imaging in detecting metastatic spread.
- Clinical management of advanced lung cancer in the UK.
The Process of Metastatic Spread in Lung Cancer
Lung cancer spreads when cells detach from the original tumour and enter the blood vessels or the network of lymph nodes and vessels that run throughout the body. Once these cells are in circulation, they can settle in a new organ and begin to multiply, forming a secondary tumour that is still composed of lung cancer cells. This process can occur at different speeds depending on the specific type of lung cancer and the genetic characteristics of the tumour.
Lung cancer can spread to other parts of the body, which is known as metastasis, most commonly through the bloodstream or the lymphatic system. In the UK, medical teams use staging tests to identify if this spread has occurred before deciding on a treatment plan. The National Institute for Health and Care Excellence (NICE) guidelines recommend that all patients potentially suitable for radical treatment should have their disease staged accurately using PET-CT or other advanced imaging.
Common Sites for Lung Cancer Metastasis
While lung cancer cells can theoretically travel anywhere in the body, they tend to settle in specific organs more frequently than others. These secondary sites are monitored closely during follow-up appointments and through staging scans. Identifying spread to these areas is essential because it shifts the clinical goal from curing the primary tumour to managing the disease systemically.
The most common areas where lung cancer may spread include:
- The liver.
- The brain.
- The bones (particularly the spine, ribs, and pelvis).
- The adrenal glands (small glands located on top of the kidneys).
- The other lung.
- Nearby lymph nodes in the centre of the chest or neck.
Distinguishing Primary and Secondary Lung Cancer
It is important to understand that if lung cancer spreads to the liver, for example, it is still treated as lung cancer rather than liver cancer. The cells in the liver will look and behave like lung cancer cells under a microscope, which means they will respond better to treatments designed for the lungs. This distinction is vital for choosing the correct chemotherapy or immunotherapy drugs.
| Feature | Primary Lung Cancer | Secondary (Metastatic) Lung Cancer |
| Origin | Starts in the tissues of the lung. | Starts in the lung and travels to another organ. |
| Cell Type | Lung-specific cells. | Lung-specific cells located in a distant site. |
| Treatment Focus | Localised (surgery/radiotherapy) or systemic. | Systemic (chemotherapy/immunotherapy). |
| Clinical Stage | Stages 1 to 3 depending on size and lymph nodes. | Stage 4 (Advanced). |
The Role of the Lymphatic System in Cancer Spread
The lymphatic system is a network of tubes and glands (lymph nodes) that filters fluid and helps the body fight infection, but it also provides a pathway for cancer cells to travel. Lung cancer often spreads first to the lymph nodes located in the centre of the chest (the mediastinum). From there, cells can move to nodes in the neck or further down into the abdomen.
Medical teams often perform a biopsy of these lymph nodes to check for cancer cells, as this is a key part of determine the clinical stage of the disease. If the lymph nodes are involved, it suggests that the cancer has begun to move beyond its original site, even if no distant spread is visible on a standard CT scan. This information helps the multidisciplinary team decide if treatments like chemotherapy are needed alongside surgery to target any microscopic cells that might be in transit.
Conclusion
Lung cancer can spread to distant organs such as the brain, liver, and bones through the blood and lymphatic systems. Identifying this spread early through staging scans is essential for ensuring that patients receive the most effective systemic treatments. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Does metastatic lung cancer always cause symptoms?
No, spread to other organs can sometimes be silent and is often only found during routine staging scans or check-ups.
Can spread to the brain be treated?
Yes, doctors can use targeted radiotherapy, surgery, or specific drugs that can reach the brain to manage these secondary tumours.
Is spread to the lymph nodes the same as Stage 4?
Not necessarily; spread to nearby lymph nodes in the chest is usually Stage 2 or 3, whereas spread to distant organs is Stage 4.
Why does lung cancer spread to the bones?
Cancer cells can travel through the bloodstream and settle in the bone marrow, which provides a rich environment for them to grow.
Can immunotherapy stop the cancer from spreading?
Immunotherapy can help the immune system find and destroy cancer cells throughout the whole body, potentially slowing or stopping further spread.
Is a liver biopsy needed if the scan shows spread?
Sometimes a doctor will biopsy a secondary site to confirm that it is indeed the lung cancer that has spread and not a different issue.
What is “extensive stage” small cell lung cancer?
This is a term used specifically for small cell lung cancer that has spread significantly within the lung or to other parts of the body.
Authority Snapshot (E-E-A-T Block)
This guide provides factual information on how lung cancer spreads, strictly following the clinical evidence and guidelines provided by the NHS and NICE. The content is reviewed by Dr. Stefan Petrov, a UK-trained physician with extensive experience in general medicine, surgery, and emergency care. Our commitment to UK medical standards ensures that this information is accurate, safe, and aligned with national diagnostic pathways.
